Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares fell 7.8% during trading on Tuesday . The stock traded as low as $24.50 and last traded at $25.30. 103,945 shares were traded during mid-day trading, a decline of 91% from the average session volume of 1,208,313 shares. The stock had previously closed at $27.43.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Regencell Bioscience Trading Down 11.2%

The firm’s fifty day moving average price is $20.81 and its 200-day moving average price is $17.06.

Institutional Trading of Regencell Bioscience

Institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd bought a new position in Regencell Bioscience in the second quarter worth $222,000. XTX Topco Ltd acquired a new position in shares of Regencell Bioscience in the 3rd quarter valued at $598,000. BNP Paribas Financial Markets bought a new position in shares of Regencell Bioscience during the 2nd quarter worth about $768,000. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience during the 2nd quarter worth about $1,701,000. Finally, Geode Capital Management LLC boosted its position in shares of Regencell Bioscience by 5,637.5% during the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after acquiring an additional 384,250 shares in the last quarter. Institutional investors and hedge funds own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.